行情

EVOK

EVOK

Evoke Pharma
NASDAQ

实时行情|Nasdaq Last Sale

0.9201
-0.0309
-3.25%
已收盘, 16:00 09/23 EDT
开盘
0.9500
昨收
0.9510
最高
0.9622
最低
0.8500
成交量
23.30万
成交额
--
52周最高
3.320
52周最低
0.5001
市值
2,218.73万
市盈率(TTM)
-2.3412
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EVOK 新闻

  • 专访纳斯达克:降息后股市会更强劲
  • 新浪财经.35分钟前
  • 观点:负利率不会很快来到美国
  • 新浪美股.43分钟前
  • 黄金期货周一收高1.1% 白银跃升4.8%
  • 新浪美股.51分钟前
  • 美联储研究报告称市场对利率降至零的预期上升
  • 新浪美股.1小时前

更多

所属板块

制药
-0.37%
制药与医学研究
-0.44%

热门股票

名称
价格
涨跌幅

EVOK 简况

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
展开

Webull提供Evoke Pharma Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。